Evidence map›Paper›PMID 37544908›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

Palmitoyltransferase ZDHHC3 Aggravates Nonalcoholic Steatohepatitis by Targeting S-Palmitoylated IRHOM2.

Minxuan Xu, Jun Tan, Liancai Zhu, Chenxu Ge, Yi Zhang, Fufeng Gao, Xianling Dai, Qin Kuang, Jie Chai, Benkui Zou and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. ProteinJournal of pharmaceutical analysis · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Palmitoylation in cardiovascular diseases: Molecular mechanism and therapeutic potential.International journal of cardiology. Heart & vasculature · 2025
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Minxuan XuChongqing Key Laboratory of Medicinal Resources in the Three Gorges Reservoir Region, School of Biological and Chemical Engineering, Chongqing University of Education, Chongqing, 400067, P. R. China.ORCID 0000-0002-0742-4717
Jun TanChongqing Key Laboratory of Medicinal Resources in the Three Gorges Reservoir Region, School of Biological and Chemical Engineering, Chongqing University of Education, Chongqing, 400067, P. R. China.
Liancai ZhuKey Laboratory of Biorheological Science and Technology (Chongqing University), Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400030, P. R. China.
Chenxu GeChongqing Key Laboratory of Medicinal Resources in the Three Gorges Reservoir Region, School of Biological and Chemical Engineering, Chongqing University of Education, Chongqing, 400067, P. R. China.
Yi ZhangDepartment of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University&Shandong Academy of Medical Science, Jinan, 250117, P. R. China.
Fufeng GaoDepartment of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University&Shandong Academy of Medical Science, Jinan, 250117, P. R. China.
Xianling DaiChongqing Key Laboratory of Medicinal Resources in the Three Gorges Reservoir Region, School of Biological and Chemical Engineering, Chongqing University of Education, Chongqing, 400067, P. R. China.
Qin KuangChongqing Key Laboratory of Medicinal Resources in the Three Gorges Reservoir Region, School of Biological and Chemical Engineering, Chongqing University of Education, Chongqing, 400067, P. R. China.
Jie ChaiDepartment of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University&Shandong Academy of Medical Science, Jinan, 250117, P. R. China.
Benkui ZouDepartment of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University&Shandong Academy of Medical Science, Jinan, 250117, P. R. China.
Bochu WangKey Laboratory of Biorheological Science and Technology (Chongqing University), Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400030, P. R. China.
Chongqing University · CNShandong Tumor Hospital · CNChongqing University of Education · CN

Funding

Chongqing Professional Talents Plan for Innovation and Entrepreneurship Demonstration Team CQCY201903258cstc2021ycjh-bgzxm0202Chongqing Research Program of Basic Research and Frontier Technology 17GZKP01Chongqing Research Program of Basic Research and Frontier Technology cstc2017jcyjAX0356Chongqing Research Program of Basic Research and Frontier Technology cstc2018jcyjA1472Chongqing Research Program of Basic Research and Frontier Technology cstc2018jcyjA3533Chongqing Research Program of Basic Research and Frontier Technology cstc2018jcyjA3686Chongqing Research Program of Basic Research and Frontier Technology cstc2018jcyjAX0784Chongqing Research Program of Basic Research and Frontier Technology cstc2018jcyjAX0811Chongqing Research Program of Basic Research and Frontier Technology KJZD-M201801601Chongqing Research Program of Basic Research and Frontier Technology KY201710BNational Natural Science Foundation of China 82200652Natural Science Foundation of Chongqing, China CSTB2022NSCQ-LZX0053Natural Science Foundation of Chongqing, China CSTB2022NSCQ-MSX0947Natural Science Foundation of Chongqing, China CSTB2022NSCQ-MSX5364Science and Technology Research Program of Chongqing Education Commission of China CSDP19FSO1108Science and Technology Research Program of Chongqing Education Commission of China KJ1601402Science and Technology Research Program of Chongqing Education Commission of China KJQN201901608Science and Technology Research Program of Chongqing Education Commission of China KJQN201901615Science and Technology Research Program of Chongqing Education Commission of China KJZD-K202001603
6 · The paper itself

Abstract

Underestimation of the complexity of pathogenesis in nonalcoholic steatohepatitis (NASH) significantly encumbers development of new drugs and targeted therapy strategies. Inactive rhomboid protein 2 (IRHOM2) has a multifunctional role in regulating inflammation, cell survival, and immunoreaction. Although cytokines and chemokines promote IRHOM2 trafficking or cooperate with partner factors by phosphorylation or ubiquitin ligases-mediated ubiquitination to perform physiological process, it remains unknown whether other regulators induce IRHOM2 activation via different mechanisms in NASH progression. Here the authors find that IRHOM2 is post-translationally S-palmitoylated at C476 in iRhom homology domain (IRHD), which facilitates its cytomembrane translocation and stabilization. Fatty-acids challenge can directly promote IRHOM2 trafficking by increasing its palmitoylation. Additionally, the authors identify Zinc finger DHHC-type palmitoyltransferase 3 (ZDHHC3) as a key acetyltransferase required for the IRHOM2 palmitoylation. Fatty-acids administration enhances IRHOM2 palmitoylation by increasing the direct association between ZDHHC3 and IRHOM2, which is catalyzed by the DHHC (C157) domain of ZDHHC3. Meanwhile, a metabolic stresses-triggered increase of ZDHHC3 maintains palmitoylated IRHOM2 accumulation by blocking its ubiquitination, consequently suppressing its ubiquitin-proteasome-related degradation mediated by tripartite motif containing 31 (TRIM31). High-levels of ZDHHC3 protein abundance positively correlate with the severity of NASH phenotype in patient samples. Hepatocyte-specific dysfunction of ZDHHC3 significantly inhibits palmitoylated IRHOM2 deposition, therefore suppressing the fatty-acids-mediated hepatosteatosis and inflammation in vitro, as well as NASH pathological phenotype induced by two different high-energy diets (HFHC & WTDF) in the in vivo rodent and rabbit model. Inversely, specific restoration of ZDHHC3 in hepatocytes markedly provides acceleration over the course of NASH development via increasing palmitoylation of IRHOM2 along with suppression of ubiquitin degradation. The current work uncovers that ZDHHC3-induced palmitoylation is a novel regulatory mechanism and signal that regulates IRHOM2 trafficking, which confers evidence associating the regulation of palmitoylation with NASH progression.

Indexed as

Non-alcoholic Fatty Liver DiseaseAnimalsFatty AcidsHumansInflammationLipoylationPhosphorylationRabbitsTripartite Motif ProteinsUbiquitin-Protein LigasesUbiquitinsFatty AcidsTRIM31 protein, humanTripartite Motif ProteinsUbiquitin-Protein LigasesUbiquitinshepatosteatosisinactive rhomboid protein 2 (IRHOM2)nonalcoholic steatohepatitis (NASH)Palmitoylationtripartite motif containing 31 (TRIM31)zinc finger DHHC-type palmitoyltransferase 3 (ZDHHC3)

Identifiers

PMID37544908
PMCPMC10558657
OpenAlexW4385613896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.